来源：器械之家，未经授权不得转载，且24小时后方可转载。 日前，跨国医械巨头波士顿科学公司宣布，已达成最终协议，收购Axonics， Inc.（纳斯达克股票代码：AXNX），这是一家上市的医疗技术公司，是骶神经刺激疗法的制造商。此次收购价格为每股71美元 ...

2024年11月15日，波士顿科学公司宣布完成对 Axonics 公司的收购。Axonics，Inc.（纳斯达克股票代码：AXNX）是一家上市的医疗技术公司，是骶神经刺激疗法的制造商。此次收购价格为每股71美元，总计股权价值约为 37 亿美元（折合人民币约为267.6亿人民币）；减去 ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

(医药健闻2024年1月11日讯)波士顿科学公司宣布已签订Axonics, Inc. 收购案的最终协议。Axonics, Inc.是一家公开上市的医疗技术公司，主要致力于开发和出售用以治疗膀胱和肠道功能障碍的新型产品。收购价格为每股71美元，以现金交易，股权价值约为37亿美元，企业 ...

Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will ...

当地时间1月8日，在旧金山举行的摩根大通医疗峰会（JPM Healthcare Conference）的第一天，波士顿科学公司（Boston Scientific）宣布已就收购Axonics达成最终协议。此次收购价格为每股71美元，比Axonics宣布交易前一个星期五的交易价格高出20%以上。股权总价值约为37亿 ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. Equity markets surged at the ...

马萨诸塞州马尔伯勒2024年11月19日 /美通社/ -- 近日，波士顿科学公司（纽约证券交易所代码：BSX）宣布完成对Axonics, Inc ...